LivingGLP1
Study S002315

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT01557166
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
359
Start
2012-06-07
Primary completion
2013-06-01
Lead sponsor
Novo Nordisk A/S
Conditions
Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea
Interventions
DRUG:liraglutide; DRUG:placebo
Results posted
TRUE
Secondary identifiers
OTHER:U1111-1126-6260

Registered primary outcomes

  • Change From Baseline in Apnoea-hypopnoea Index (AHI) [Week 0, Week 32]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0013170Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.
Davies MJ, Diabetes, obesity & metabolism
2018Systematic reviewPMID 28950422DOIregistry reference RESULT:28950422
R0022210Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
O'Neil PM, Diabetes, obesity & metabolism
2017Randomized trialPMID 28386912DOIregistry reference RESULT:28386912
R0025365Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program.
Steinberg WM, Diabetes care
2017Randomized trialPMID 28473337DOIregistry reference RESULT:28473337
R0025976Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.
Bays H, Current medical research and opinion
2017Randomized trialPMID 27817208DOIcites ClinicalTrials.gov:NCT01557166; registry reference RESULT:27817208
R0026203Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
Blackman A, International journal of obesity (2005)
2016Randomized trialPMID 27005405DOIcites ClinicalTrials.gov:NCT01557166; registry reference RESULT:27005405
R0026243EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
O'Neil PM, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2016Randomized trialPMID 27482610DOIregistry reference RESULT:27482610